Why the study?
Dysfunctional endothelium has received increasing attention in diabetic vascular disease pathogenesis, motivating a presentation of state-of-the-art data regarding endothelial dysfunction in diabetic micro- and macroangiopathy.
This systematic review summarizes current evidence on the pathophysiological role of endothelial dysfunction in diabetic angiopathy and potential molecular pharmacological approaches.
Endothelial dysfunction may inform vascular risk assessment in DM; leaves open targeted interventions pending prospective validation.
Diabetes mellitus (DM) is a frequent medical problem, affecting more than 4% of the population in most countries. In the context of diabetes, the vascular endothelium can play a crucial pathophysiological role. If a healthy endothelium-which is a dynamic endocrine organ with autocrine and paracrine activity-regulates vascular tone and permeability and assures a proper balance between coagulation and fibrinolysis, and vasodilation and vasoconstriction, then, in contrast, a dysfunctional endothelium has received increasing attention as a potential contributor to the pathogenesis of vascular disease in diabetes. Hyperglycemia is indicated to be the major causative factor in the development of endothelial dysfunction. Furthermore, many shreds of evidence suggest that the progression of insulin resistance in type 2 diabetes is parallel to the advancement of endothelial dysfunction in atherosclerosis. To present the state-of-the-art data regarding endothelial dysfunction in diabetic micro- and macroangiopathy, we constructed this literature review based on the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). We interrogated five medical databases: Elsevier, PubMed, PMC, PEDro, and ISI Web of Science.
No takes yet. Share an insight, caveat, or question.
Munteanu et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: